Adolescent depression

Article written and reviewed by Dr Luca Moretti

Adolescent depression refers to the onset of a depressive disorder during adolescence and does not constitute a separate diagnosis from DSM-5-TR or ICD-11 categories. Its clinical specificity derives from the fact that the disorder occurs during a phase characterized by pubertal maturation, increasing autonomy, reorganization of family and peer relationships, identity development and growing academic and social demands.

The diagnostic core remains that of depressive disorders, but expression may differ from that in adults. DSM-5-TR allows irritable mood to substitute for depressed mood in the major depressive episode criterion in children and adolescents. Irritability, social withdrawal, loss of interest, worsening school performance, changes in sleep and appetite, self devaluation, self harm and suicidal ideation must, however, be interpreted as part of a syndromic picture and not as isolated synonyms for depression.

Adolescence coincides with a marked increase in the frequency of depressive disorders. The World Health Organization estimates that depression affects approximately 1.3% of 10 to 14 year olds and 3.4% of 15 to 19 year olds, although figures vary across countries, instruments and definitions. After puberty, a clear sex difference also emerges, with a higher prevalence in girls than in boys; the gap is not explained by a single endocrine mechanism but probably by interactions among biological maturation, psychological vulnerability and social exposures.

Depression during this phase has particular prognostic relevance because it can interfere with academic performance, relationships, development of autonomy and transition to adulthood. Longitudinal studies and meta analyses associate adolescent depression with a higher risk of recurrent depression, other psychiatric disorders and later difficulties in education, employment and relationships. These associations do not represent an inevitable destiny, and effective treatment changes the clinical trajectory.

Adolescents may not spontaneously seek help. Shame, fear of being judged, the belief that problems are “normal”, a desire for autonomy or difficulty recognizing change may delay diagnosis. On the other hand, normal adolescent emotional fluctuations should not be pathologized: what distinguishes the disorder is the combination of persistence, pervasiveness, distress and functional impairment.

Suicide risk carries much greater weight in adolescence than in childhood. WHO ranks suicide among the leading causes of death in young people; depression, previous attempts, self harm, substance use, impulsivity, hopelessness, isolation and access to lethal means contribute to risk. Safety assessment should therefore be explicit in every adolescent with depressive symptoms and repeated during follow up.

Etiology, Pathogenesis and Pathophysiology

Adolescent depression has a multifactorial etiology. Genetic predisposition, neurobiological development, puberty, temperament, cognitive styles, adverse events, relationships, sleep and comorbidities interact in determining vulnerability. None of these factors is sufficient, and it is scientifically incorrect to attribute the disorder to a single cause such as “hormones”, social media use, family conflict or a serotonin deficiency.

A family history of depression and bipolar disorder increases risk, reflecting shared genetic and environmental components. The genetic architecture of depression is polygenic, with very many variants of small effect. There are no genetic tests in adolescents capable of confirming the diagnosis or determining which treatment will work with reliable individual clinical accuracy.

Puberty temporally coincides with the rise in incidence and emergence of the sex difference. Systematic reviews show associations between pubertal progression and depressive symptoms, especially in girls, but chronological age, biological maturation and social context are closely correlated. Gonadal hormones influence brain circuits and stress responses, but there is no single endocrine alteration responsible for adolescent depression.

Adverse life events and interpersonal stress are important risk factors. Maltreatment, bullying and cyberbullying, violence, discrimination, loss, relationship conflict and isolation can increase the likelihood of depression. Associations are bidirectional and conditioned by individual vulnerability: an adolescent with depression may also withdraw, enter conflict more readily or perceive interactions more negatively, thereby contributing to persistence of the disorder.

The digital environment warrants specific but cautious assessment. Problematic use, cyberbullying, sleep disruption and social comparison may be associated with poorer wellbeing, while online activities may also provide connection and support. Observational evidence does not allow the simple number of hours spent on social media to be identified as a direct cause of depression in an individual adolescent; it is more useful to investigate patterns of use, content, impact on sleep and functioning.

Sleep is an important pathophysiological and clinical node. The normal adolescent circadian delay, school schedules, evening device use and insomnia can reduce sleep duration. Persistent sleep disturbances can precede, accompany and maintain depression and should be treated without automatically attributing every case of insomnia to the mood disorder.

At the level of brain circuits, adolescence is characterized by asynchronous maturation of reward, salience and prefrontal control systems. In depression, mean alterations in the processing of reward, threat, emotions and self referential processes have been described. These differences have research value and are not specific enough to permit diagnosis by magnetic resonance imaging or other neurofunctional examinations.

Serotonin, norepinephrine and dopamine participate in mood regulation and are pharmacological targets, but the hypothesis of a simple monoamine deficiency does not adequately describe pathophysiology. Synaptic plasticity, glutamatergic systems, neurotrophic factors, stress regulation and emotional learning processes are part of more complex and interconnected models.

Negative cognitive styles, rumination, self criticism and rejection sensitivity may become more elaborate during adolescence as abstract thinking develops. These processes are not merely consequences of mood: they can maintain the disorder by directing attention and memory toward negative information and reducing the ability to use positive experiences as corrective information.

Withdrawal from sports, friends and rewarding activities reduces positive reinforcement and can fuel anhedonia and passivity. At the same time, school failures or conflicts resulting from depression can become new stressors. This cycle between symptoms and environment is one rationale for behavioral activation and interpersonal interventions.

Anxiety disorders, ADHD, eating disorders, substance use, trauma and neurodevelopmental conditions are common or clinically relevant comorbidities. They may share risk factors, precede depression or emerge as consequences of common difficulties. Pathophysiology should therefore be understood as a network of vulnerabilities rather than a single causal sequence.

Adolescence is also a phase in which bipolar disorder may first become manifest. A depressive episode can precede the first mania or hypomania by years; family history, episodes of activation, decreased need for sleep and the longitudinal history of energy and activity should therefore be explored without automatically labeling every case of youth depression as bipolar.

There are no validated blood, endocrine, genetic or neuroimaging biomarkers for diagnosing depression in adolescents. Biological research clarifies mechanisms and subgroups, but diagnosis remains clinical and longitudinal.

Clinical Manifestations

Clinical assessment begins by reconstructing the trajectory of the previous weeks or months and comparing it with previous functioning. It is useful to ask the adolescent and caregivers separately when the change in mood, withdrawal, decline in school performance, sleep disturbance and relationship difficulties began, avoiding reducing the interview to a checklist of symptoms.

Except in situations requiring different management for safety reasons, the adolescent should have access to a confidential interview space. Information about suicidality, sexuality, substances, violence, relationships and family experiences may not emerge in the presence of parents. The limits of confidentiality should be explained clearly, particularly when there is a concrete risk to the patient or others.

Mood may be described as sadness, emptiness, hopelessness or worthlessness, but irritability may predominate. An adolescent with depression may become more argumentative and intolerant of frustration; however, isolated irritability, family conflict or oppositional behavior is not sufficient to diagnose depression.

Anhedonia may be evident in abandonment of sports, music, friendships, previously rewarding online activities or romantic relationships. It may manifest as an inability to anticipate pleasure or as reduced pleasure during the activity. Loss of motivation should not automatically be confused with laziness or lack of effort.

School functioning may deteriorate because of concentration difficulties, fatigue, insomnia, absences and loss of motivation. Declining academic performance is an important but nonspecific sign: ADHD, learning disorders, bullying, substance misuse, family problems and numerous medical conditions can produce a similar presentation.

Sleep and circadian rhythm require a detailed history. Initial insomnia, awakenings, nonrestorative sleep or hypersomnia may occur, but depressive symptoms must be distinguished from the physiological delay of the adolescent rhythm and sleep deprivation related to schedules. A marked decreased need for sleep without fatigue instead suggests possible hypomania or mania and requires further assessment.

Appetite and weight may decrease or increase. Assessment should distinguish the neurovegetative change of depression from voluntary restriction, binge eating, compensatory behaviors and concern about weight and body shape typical of feeding and eating disorders, which may coexist with depression and increase clinical risk.

Loss of energy, psychomotor slowing and cognitive difficulties can lead to reduced self care and daily activities. In other adolescents, agitation, restlessness and anxiety predominate. Clinical observation should establish whether psychomotor changes are actually present rather than simply reported.

Self devaluation, guilt and pessimism may focus on physical appearance, school results, relationships or identity. Hopelessness is particularly relevant to suicide risk and should be explored directly, without assuming that an adolescent who appears sociable or can joke cannot have thoughts of death.

Nonsuicidal self injury, for example cutting or other intentional injury without intent to die, is not a diagnostic criterion for depression but is frequently associated with emotional distress and increases the complexity of assessment. It should be distinguished from a suicide attempt on the basis of intent, while remembering that the two forms of behavior may coexist in the same patient.

Suicide assessment should distinguish passive thoughts of death, active ideation, intent, plan, preparations, access to means and previous attempts. Dynamic factors such as a recent relationship breakup, humiliation, intoxication, agitation, insomnia and acute conflict should also be sought. Risk estimation cannot be reduced to the result of a scale.

Use of alcohol, cannabis, stimulants, sedatives and other substances should be investigated without judgment. Substances may precede, accompany or worsen depression, disrupt sleep, increase impulsivity and make treatment response less reliable. It is important to establish chronology and quantity rather than assume automatic causality.

Symptoms of anxiety, panic, obsessions, trauma, eating disorders and ADHD should be sought. A history of elevated mood, grandiosity, pathological increase in activity, disinhibited behavior or decreased need for sleep requires assessment for bipolarity. Psychotic symptoms may occur in severe depressive forms but also require differential diagnosis with primary psychotic disorders.

Mental status examination evaluates appearance, cooperation, psychomotor activity, speech, mood, affect, form and content of thought, perceptions, attention, insight and judgment. Presentation may change rapidly depending on context, so a single interview must be integrated with the longitudinal history and relevant collateral information.

Assessment and Diagnosis

There are no separate criteria for a diagnosis called “adolescent depression”. The criteria for the relevant depressive disorder are applied, with adaptations expressly provided for developmental age. In major depressive disorder, the core is the major depressive episode followed by exclusion of bipolarity, substances, medical conditions and other diagnoses that better explain the presentation.

DSM-5-TR criteria applicable to major depressive disorder in adolescents

• During the same period of at least two weeks, at least five symptoms must be present, representing a change from previous functioning; at least one must be depressed or irritable mood or a marked reduction in interest or pleasure.
• Depressed mood for most of the day and on most days; in adolescents the criterion may be met by persistent irritable mood.
• Markedly diminished interest or pleasure in all or almost all activities for most of the day and on most days.
• Significant unintended weight loss or gain, or decreased or increased appetite; in adolescents who are still growing, failure to make expected weight gains should also be considered.
• Insomnia or hypersomnia nearly every day.
• Psychomotor agitation or retardation nearly every day, observable by others and not limited to a subjective feeling.
• Fatigue or loss of energy nearly every day.
• Feelings of worthlessness or excessive or inappropriate guilt nearly every day.
• Diminished ability to think or concentrate, or indecisiveness, nearly every day, reported by the patient or observed by others.
• Recurrent thoughts of death, recurrent suicidal ideation, a suicide attempt or suicide planning.
• The symptoms as a whole must cause clinically significant distress or impairment in social, school, family or other important areas of functioning.
• The episode must not be attributable to the physiological effects of a substance or another medical condition.
• To diagnose major depressive disorder, the presentation must not be better explained by schizophrenia spectrum disorders or other psychotic disorders and there must be no history of a manic or hypomanic episode.

Diagnosis requires an interview with the adolescent and information from parents or caregivers, supplemented when necessary by school information. Assessment must define duration, severity and impairment, as well as previous episodes, family history, comorbidities, development, medications, substances and social factors.

Questionnaires such as the PHQ-9 modified for adolescents and other validated instruments can be used for screening and monitoring. Screening is not equivalent to diagnosis: a high score should be followed by a clinical interview, while a low score does not eliminate the need for further assessment when the history or behavior suggests significant risk.

Screening recommendations vary by age and health care system. Evidence more strongly supports screening adolescents for depression when systems are in place to confirm diagnosis and ensure treatment and follow up. Screening in isolation, without a care network, does not constitute a complete care strategy.

Suicide assessment should also be performed when the initial reason for the visit is school related, somatic or anxiety related. No scale predicts suicide in an individual with sufficient accuracy; clinical judgment integrates ideation, intent, plan, previous behaviors, available means, substances, impulsivity, supports and the ability to collaborate on a safety plan.

Differential diagnosis with bipolar disorder is essential before starting an antidepressant. Distinct episodes of increased energy or activity associated with pathological elevation or irritability, decreased need for sleep, grandiosity, pressured speech, flight of ideas, increased goal directed activity or risky behavior should be sought. Irritability and lability alone do not demonstrate bipolarity.

Anxiety disorders and trauma can cause withdrawal, insomnia and concentration difficulties. ADHD and learning disorders can explain school failure. Eating disorders may present with weight loss, withdrawal and irritability. Chronology and the presence of the depressive core help distinguish primary depression, comorbidity or another diagnosis.

Substance use should be assessed to distinguish a primary depressive disorder from symptoms related to intoxication, withdrawal or consequences of use. The mere presence of cannabis or alcohol does not justify considering all symptoms “substance induced”; the temporal and clinical relationship must be established.

Bereavement, relationship breakups and stressful events do not exclude a major depressive episode. Adjustment disorder is considered when the response to the stressor meets its requirements and is not better explained by another disorder. Assessment should avoid both automatically medicalizing a transient reaction and trivializing severe depression because an apparent cause exists.

Laboratory investigations are selective. History and physical examination may suggest a complete blood count, TSH, metabolic testing, pregnancy testing when relevant or other investigations. Neuroimaging, EEG and extensive hormonal testing are not routine in depression in the absence of neurological signs, atypical cognitive changes, seizures or other specific features.

Medical assessment includes sleep, growth, nutrition, menstrual cycle when relevant, pain, chronic disease and medications. An organic condition can coexist with depression; there is no need to choose between “organic” and “psychological” when both contribute to disability.

The final formulation should include the specific disorder, severity, suicide risk, any mixed or psychotic features, comorbidities, substances, functioning and protective factors. This formulation guides the level of care and allows monitoring over time not only of symptoms but also of recovery in school, family and social functioning.

Treatment and Prognosis

Treatment requires shared decision making among the adolescent, family and professionals, calibrated to severity and safety. In mild presentations, psychological and psychosocial interventions with monitoring may be used, whereas moderate or severe depression requires structured and more intensive treatment. Caregiver involvement is important, but should progressively respect the adolescent's autonomy and confidentiality.

According to NICE, for young people aged 12 to 18 with moderate to severe depression, individual CBT is one of the main options, with alternatives including interpersonal psychotherapy for adolescents, family therapies, brief psychosocial interventions or psychodynamic psychotherapy when better suited to the case. The 2023 AACAP guidelines recommend evidence based psychotherapies and, when indicated, SSRI antidepressants, with individualized selection.

Cognitive behavioral therapy addresses avoidance, rewarding activities, negative thoughts and problem solving. Interpersonal psychotherapy focuses intervention on relationships and role transitions, aspects that are particularly relevant during adolescence. Family therapies may be useful when communication, conflict or caregiver difficulties interfere with recovery, without implying that the family is the cause of depression.

For moderate to severe depression, particularly when response to psychotherapy alone is insufficient, fluoxetine is the antidepressant with the most established support and has a European indication from age 8 for moderate to severe major depressive episodes that have not responded to psychotherapy after 4 to 6 sessions. NICE also considers combined fluoxetine plus psychotherapy for those aged 12 to 18.

Other SSRIs may be used in specific specialist settings, but regulatory approvals and strength of evidence vary among drugs and countries. It is not appropriate to automatically extrapolate the entire adult pharmacological algorithm to adolescents. Selection should consider previous responses, comorbidities, interactions, overdose risk and preferences.

During antidepressant treatment, active monitoring of suicidal ideation, agitation, hostility, clinical worsening and possible activation symptoms is required. European regulatory authorities have drawn attention to the increase in suicidal thoughts or behaviors observed in young people treated with some antidepressants. This risk must be balanced against the risk of untreated depression and justifies neither indiscriminate prescribing nor categorical rejection of medication.

Before and during pharmacotherapy, possible emergence of mania or hypomania should be monitored. A switch with a clear increase in energy, decreased need for sleep, grandiosity or disinhibition requires diagnostic and therapeutic reassessment. Simple initial restlessness does not automatically equal mania, but should be interpreted clinically.

Treatment should include sleep, daily activities, substance use and school problems. A realistic plan for returning to or maintaining school attendance can prevent prolonged absence from consolidating avoidance and isolation. Physical activity and regular routines are useful components, but do not replace validated therapies in moderate to severe presentations.

In patients who self harm, it is necessary to understand its function, triggers and relationship to suicidal intent. The safety plan should include warning signs, immediate strategies, people to contact, access to services and reduction of access to lethal means. So called “no suicide contracts” do not replace assessment and a structured safety plan.

Hospital admission or urgent assessment becomes necessary when risk cannot be safely managed in an outpatient setting, in the presence of a recent high lethality attempt, severe psychosis, catatonia, severe self neglect or inability of the family network to provide protection. The level of care should be determined by current risk, not by diagnosis alone.

In treatment resistant depression, adherence, adequacy of psychotherapy, medication duration and dose, bipolarity, substances and comorbidities must be reviewed before multiplying therapies. Second line pharmacological strategies in adolescents have more limited evidence than in adults and require specialist child and adolescent neuropsychiatry care.

Electroconvulsive therapy may have a rare but important role in adolescents with extremely severe, psychotic, catatonic or treatment resistant depression when a rapid response is needed, in experienced centers and according to applicable regulations and consent requirements. Neuromodulation techniques and glutamatergic treatments have much more limited pediatric evidence than in adults and should not be presented as routine.

Remission should include functional recovery, not merely reduced scores: sleep, relationships, school, autonomy, interest and activity should be reassessed. Residual symptoms increase relapse risk and justify continuation of treatment and follow up.

Prognosis is variable. Many adolescents achieve remission, but recurrence is common and depression in young people is associated with a greater risk of mood disorders and psychosocial difficulties in adulthood. Severe or repeated episodes, suicidality, comorbidities, residual symptoms and persistent stress are associated with a less favorable prognosis without allowing certain predictions for an individual.

Complications

The most serious complication is suicide. Risk increases in the presence of previous attempts, ideation with intent and a plan, severe depression, hopelessness, agitation, substance use and access to lethal means. Assessment must be dynamic because an adolescent can move rapidly from passive ideation to high risk behavior.

Nonsuicidal self injury can become repetitive and be associated with dysfunctional emotional regulation, shame and interpersonal difficulties. Although it is not equivalent to a suicide attempt, it identifies a population requiring particular attention and treatment of underlying conditions.

Depression can cause absences, reduced performance and school dropout. Educational consequences can persist beyond remission of the episode and influence training and employment opportunities, which is why school recovery should be considered a genuine clinical goal.

Social withdrawal can erode friendships and support, increasing loneliness and reliance on online interactions that are not always protective. Loss of belonging can become a maintenance factor and requires gradual interventions to rebuild meaningful connections.

Alcohol, cannabis or other substances may be used in an attempt to manage anxiety, insomnia or distress. The result can be increased impulsivity, worse sleep, lower adherence and greater suicide risk. Comorbid substance use requires integrated treatment.

Eating disorders, anxiety, trauma and ADHD may emerge or become more evident during the course. The presence of multiple conditions increases overall disability and requires a therapeutic hierarchy based on risk and impairment rather than a rigid sequence of diagnoses.

Depression can impair family relationships through irritability, withdrawal and conflict, while conflict can in turn worsen symptoms. Treatment involving the family when indicated can interrupt this cycle without assigning blame.

Relapses and recurrences are common. A new episode may occur after months or years, and risk increases with previous episodes and incomplete remission. The adolescent and family should know prodromal signs and have a defined pathway for rapidly requesting reassessment.

In some patients, the subsequent course reveals bipolar disorder. A first depressive episode cannot predict this evolution with certainty, but the emergence of mania or hypomania changes diagnosis and treatment. Longitudinal follow up is therefore particularly important in early onset presentations.

Population studies associate adolescent depression with less favorable psychosocial outcomes in adulthood. These findings reflect both effects of the disorder and shared vulnerabilities and comorbidities; they should not be presented as inevitable consequences. Complete remission and functional recovery remain realistic goals.

Bibliography
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing; 2022.
2. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization; 2024.
3. Walter HJ et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 62(5), 2023: 479-502.
4. National Institute for Health and Care Excellence. Depression in children and young people: identification and management. NICE guideline NG134. National Institute for Health and Care Excellence; 2019, updated 2025.
5. Thapar A et al. Depression in young people. Lancet. 400(10352), 2022: 617-631.
6. World Health Organization. Mental health of adolescents. World Health Organization; 2025.
7. Stumper A et al. Associations Between Pubertal Stage and Depression: A Systematic Review of the Literature. Child Psychiatry Hum Dev. 54(2), 2023: 312-339.
8. Zhou X et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 7(7), 2020: 581-601.
9. Cipriani A et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 388(10047), 2016: 881-890.
10. March J et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study randomized controlled trial. JAMA. 292(7), 2004: 807-820.
11. Oud M et al. Effectiveness of CBT for children and adolescents with depression: A systematic review and meta-regression analysis. Eur Psychiatry. 57, 2019: 33-45.
12. Clayborne ZM et al. Systematic Review and Meta-Analysis: Adolescent Depression and Long-Term Psychosocial Outcomes. J Am Acad Child Adolesc Psychiatry. 58(1), 2019: 72-79.
13. Viswanathan M et al. Screening for Depression and Suicide Risk in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 328(15), 2022: 1543-1556.
14. European Medicines Agency. Prozac and associated names: referral information and conditions for use in children and adolescents. European Medicines Agency; 2006.
15. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression, Revision 3. European Medicines Agency; 2025.